Compared with the control group, the OTSSP167 treatment group showed a significantly lower number of Ki67-positive cells and downregulated MELK and p-AKT(Ser473) expression, which coincided with the results of the in vitro experiments (Figure 6G), indicating that OTSSP167 inhibits the proliferation of GBM cells in vivo by inhibiting the expression of MELK and the phosphorylation of AKT. Here, MELK is linked to glioblastoma.